Temomedac 100 mg hard capsules
Sponsors
Erasca Inc., Deciphera Pharmaceuticals Inc.
Conditions
Relapsed/refractory primary central nervous system lymphomaUnresectable or metastatic NRAS mutant cutaneous melanoma
Phase 3
A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE OR METASTATIC NRAS MUTANT CUTANEOUS MELANOMA COMPARING THE COMBINATION OF NAPORAFENIB + TRAMETINIB TO PHYSICIAN’S CHOICE OF THERAPY (DACARBAZINE, TEMOZOLOMIDE OR TRAMETINIB MONOTHERAPY) WITH A DOSE OPTIMIZATION LEAD-IN [SEACRAFT-2]
RecruitingCTIS2024-511404-17-00
Start: 2024-10-07Target: 294Updated: 2026-01-07
A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants with Relapsed/Refractory Primary Central Nervous System Lymphoma
Not yet recruitingCTIS2025-523389-26-00
Target: 6Updated: 2026-05-14